Home > Insider Trading > Filing (0000950170-25-008451)

Filing Details

Accession Number:: 0000950170-25-008451
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-01-23 19:01:20
Reporting Period:: 2025-01-21

Accepted Time:: 2025-01-23 19:01:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1812364	Relay Therapeutics Inc.	RLAY	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816210	Sanjiv Patel	C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02142	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-21	125,000	$4.52	449,548	No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019
Common Stock	Disposition	2025-01-22	125,000	$4.80	324,548	No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019
Common Stock	Disposition	2025-01-23	125,000	$4.78	199,548	No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019
No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019
No	4	S	Indirect	By The Patel Family Irrevocable Trust of 2019

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	766,130	Direct
Common Stock	687,355	Indirect	By The SSP Irrevocable Trust of 2020

Footnotes

These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024.
This transaction was executed in multiple trades at prices ranging from $4.35 to $4.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
This transaction was executed in multiple trades at prices ranging from $4.65 to $4.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades at prices ranging from $4.62 to $4.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 762,360 shares underlying restricted stock units.
These shares are held in an irrevocable trust for the benefit of the reporting person's family members. An independent trustee is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.